Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-19. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
indicate that the four-fold degeneracy (two valley and two spin degrees of freedom) of the Landau energy levels is partially or completely lifted. One hypothesis proposes that magnetic catalysis of symmetry breaking is responsible for this degeneracy lift.
== Taxonomy == The taxonomy of the genus Channa is incomplete, and a comprehensive revision of the family has not been performed. A phylogenetic study in 2010 has indicated the likelihood of the existence of undescribed species of channids in Southeast Asia, and a more comprehensive phylogenetic study in 2017 indicated that several undescribed species exist in Asia (as well as an undescribed Parachanna in Africa). In 2011, the Malabar snakehead Channa diplogramma from peninsular India was shown to be a distinct species, 146 years after its initial description and 134 years after it was synonymised with C. micropeltes, establishing it is an endemic species of peninsular India. The study also suggested that the species shared a most recent common ancestor with C. micropeltes, around 9.52 to 21.76 MYA.
NADH + H+ + acceptor ⇌ NAD+ + reduced acceptor NADH dehydrogenase is a flavoprotein that contains iron-sulfur centers. There are two main enzymes often referred to as NADH dehydrogenase, both involving a quinone as an acceptor. NADH dehydrogenase (H(+)-translocating), also known as Complex I (EC 7.1.1.2) is an proton pump which is part of the electron transport chain which is vital for ATP production in eukaroyotes. The other type, NADH dehydrogenase (non-energetic) (EC 1.6.5.9) refers to an enzyme found in yeast, plants, and some aerobic bacteria that catalyzes a similar reaction, but without pumping protons.
=== Covalently bound lipid anchors === Lipid anchored proteins are covalently attached to different fatty acid acyl chains on the cytoplasmic side of the cell membrane via palmitoylation, myristoylation, or prenylation. On the exoplasmic face of the cell membrane, lipid anchored proteins are covalently attached to the lipids glycosylphosphatidylinositol (GPI) and cholesterol. Protein association with membranes through the use of acylated residues is a reversible process, as the acyl chain can be buried in a protein's hydrophobic binding pocket after dissociation from the membrane. This process occurs within the beta-subunits of G-proteins. Perhaps because of this additional need for structural flexibility, lipid anchors are usually bound to the highly flexible segments of proteins tertiary structure that are not well resolved by protein crystallographic studies.
=== Energy and entropy === The microscopic features of liquids derive from an interplay between attractive intermolecular forces and entropic forces. The attractive forces tend to pull molecules close together, and along with short-range repulsive interactions, they are the dominant forces behind the regular structure of solids. The entropic forces are not "forces" in the mechanical sense; rather, they describe the tendency of a system to maximize its entropy at fixed energy (see microcanonical ensemble). Roughly speaking, entropic forces drive molecules apart from each other, maximizing the volume they occupy. Entropic forces dominant in gases and explain the tendency of gases to fill their containers. In liquids, by contrast, the intermolecular and entropic forces are comparable, so it is not possible to neglect one in favor of the other. Quantitatively, the binding energy between adjacent molecules is the same order of magnitude as the thermal energy
Sources: en.wikipedia.org
== External links == Laws, ordinances, guidelines, expert opinions and publications on radiation protection Archived 2018-03-18 at the Wayback Machine, timeline since 2002 of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection. Retrieved on November 28, 2017. Guidelines for quality assurance in radiology Archived 2013-07-15 at the Wayback Machine (PDF) German Medical Association, November 23, 2007. Retrieved December 4, 2017. DIN Radiology Standards Archived 2013-07-15 at the Wayback Machine (PDF) DIN Radiology Standards Committee NAR in cooperation with the German Radiological Society, June 2015, accessed December 4, 2017. Radiation protection in veterinary medicine - Guideline to the Radiation Protection Ordinance (StrlSchV) and the X-ray Ordinance (RöV) (PDF) September 25, 2014, Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety, Division Medical-Biological Affairs of Radiation Protection Ref. RS II 4 - 11432/7. Retrieved November 28, 2017. Radioactivity and radiation protection (PDF; 6.6 MB) Federal Office of Public Health (Switzerland), July 2007, accessed November 25, 2017. Overview of international radiation protection associations and organizations, Austrian Association for Radiation Protection. Retrieved December 3, 2017. Human Radiation Experiments DOE Openness. Retrieved January 10, 2018. Department of Energy OpenNet Resources. Retrieved January 10, 2018. Igor Gusev, Angelina Guskova, Fred A. Mettler: Medical Management of Radiation Accidents, Second Edition.
=== Career === In 1966, Kenyon started as an assistant professor of biology at San Francisco State University and became emeritus in 2001. In 1969, Kenyon co-authored Biochemical Predestination with Gary Steinman. Chemist Stephen Berry explained Kenyon's and Steinman's theory as "describing the following causal chain: the properties of the chemical elements dictate the types of monomers that can be formed in prebiotic syntheses, which then dictate the properties of the occurring polymers, which finally dictate the properties of the first eobionts and all succeeding cells." Kenyon's work was about virus production. During the 1969–1970 academic year he was "on a fellowship at the Graduate Theological Union in Berkeley, where he reviewed the contemporary literature on the relationship of science and religion." Then in 1974, he was a visiting scholar to Trinity College, Oxford. Kenyon states that his views changed around 1976 after exposure to the work of young Earth creationists:
=== Mood and stress === The involvement of KOR in stress, as well as in consequences of chronic stress such as depression, anxiety, anhedonia, and modulating drug-seeking behavior, has been widely investigated. KOR is postulated to play an important and varied role in regulating various affective state and stress responses in humans through multiple complex processes. There have been numerous studies implicating KOR in pathology of various psychiatric disorders. One of the main premises for this investigation comes from the receptor activation causing cellular hyperpolarization and, in neurons, decreased neurotransmitter release through a reduction in calcium and increase in potassium conductance. Through these mechanisms, KORs are thought to regulate the release of many signaling molecules including: γ-aminobutyric acid (GABA), glutamate, serotonin, dopamine, norepinephrine. Results on exact influence on neuronal activity and neurotransmitter release vary in vivo. KOR activation elicits immediate hyperpolarization of dopamine neurons (in 1–2 min), followed by decreased dopamine release (5–10 min) and secondary effects on serotonin and glutamate (10–30 min).
=== Emerging orthopoxvirus infections === With the eradication of smallpox, the remaining Orthopoxvirus infection of great human consequence is Mpox, a disease endemic to West and Central Africa. A number of regional Mpox outbreaks lead to the renewal of a speculation that a poxvirus closely related to smallpox such as Mpox or cowpox could become adapted to humans over time and take up the ecological niche vacated by the extinction of smallpox. Among the requried adaptations for this niche is human-to-human transmission: this is known to occur in these small Mpox outbreaks, albeit inefficient enough for these outbreaks to stay local. The 2022–2023 mpox outbreak was unusual in that it featured higher rates of human-to-human transmission than previous regional outbreaks, allowing it to spread throughout the world to affect 121 countries and territories. The WHO declared a public health emergency of international concern (PHEIC) for this clade IIb outbreak on 23 July 2022 and smallpox vaccines were used off label (or given emergency approval) for Mpox prevention. A new 2023–2026 mpox epidemic by a novel clade Ib caused an (ongoing) epidemic in Central Africa, especially DR Congo, with limited local transmission in a few countries outside of Africa. At the same time, cases caused by descendants of the 2022 outbreak continues occurring at a low rate outside of Africa.
Sources: en.wikipedia.org
Most sexually reproducing organisms are diploid, with paired chromosomes, but doubling of their chromosome number may occur due to errors in cytokinesis. This can occur early in development to produce an autopolyploid or partly autopolyploid organism, or during normal processes of cellular differentiation to produce some cell types that are polyploid (endopolyploidy), or during gamete formation. An allopolyploid plant may result from a hybridisation event between two different species. Both autopolyploid and allopolyploid plants can often reproduce normally, but may be unable to cross-breed successfully with the parent population because there is a mismatch in chromosome numbers. These plants that are reproductively isolated from the parent species but live within the same geographical area, may be sufficiently successful to form a new species. Some otherwise sterile plant polyploids can still reproduce vegetatively or by seed apomixis, forming clonal populations of identical individuals. Durum wheat is a fertile tetraploid allopolyploid, while bread wheat is a fertile hexaploid. The commercial banana is an example of a sterile, seedless triploid hybrid. Common dandelion is a triploid that produces viable seeds by apomictic seed. As in other eukaryotes, the inheritance of endosymbiotic organelles like mitochondria and chloroplasts in plants is non-Mendelian. Chloroplasts are inherited through the male parent in gymnosperms but often through the female parent in flowering plants.
Most LFTs are intended to operate on a purely qualitative basis. However, it is possible to measure the intensity of the test line to determine the quantity of analyte in the sample. Handheld diagnostic devices known as lateral flow readers are used by several companies to provide a fully quantitative assay result. By utilizing unique wavelengths of light for illumination in conjunction with either CMOS or CCD detection technology, a signal-rich image can be produced of the actual test lines. Using image processing algorithms specifically designed for a particular test type and medium, line intensities can then be correlated with analyte concentrations. One such handheld lateral flow device platform is made by Detekt Biomedical L.L.C. Alternative non-optical techniques are also able to report quantitative assays results. One such example is a magnetic immunoassay (MIA) in the LFT form also allows for getting a quantified result. Reducing variations in the capillary pumping of the sample fluid is another approach to move from qualitative to quantitative results. Recent work has, for example, demonstrated capillary pumping with a constant flow rate independent from the liquid viscosity and surface energy.
In view of its widespread use, toxicity, and volatility, formaldehyde poses a significant danger to human health. In 2011, the US National Toxicology Program described formaldehyde as "known to be a human carcinogen".
R−H + M+ = R−M + H+. Similar to anion resins, in cation resins the regeneration involves the use of a strongly acidic solution, e.g. aqueous hydrochloric acid. During regeneration, the regenerant chemical passes through the resin and flushes out the trapped positive ions, renewing the resin exchange capacity.
==== Memoirs ==== Peart, Neil. Far and Wide: Bring that Horizon to Me! ECW Press, 2016. ISBN 978-1770413481. Peart, Neil. Ghost Rider: Travels on the Healing Road. ECW Press, 2002. ISBN 1-55022-546-4 (hardcover), ISBN 1-55022-548-0 (paperback). Peart, Neil. The Masked Rider: Cycling in West Africa. Pottersfield Press, 1996. ISBN 1-895900-02-6. Peart, Neil. Roadshow: Landscape With Drums – A Concert Tour By Motorcycle. Rounder Books, 2006. ISBN 1-57940-142-2. Peart, Neil. Traveling Music: Playing Back the Soundtrack to My Life and Times. ECW Press, 2004. ISBN 1-55022-664-9. Lee, Geddy. Geddy Lee's Big Beautiful Book of Bass. HarperCollins Publishers, 2018. ISBN 9780062747839. Lee, Geddy. My Effin' Life. HarperCollins Publishers, 2023. ISBN 9780063159426
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.